Open AccessA perspective on the widening gap between Covishield vaccine doses in India
Author(s) -
Lalithambigai Chellamuthu,
Sinthu Sarathamani,
Abhijit Vinodrao Boratne
Publication year - 2021
Publication title -
indian journal of community health/indian journal of community health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 9
eISSN - 2248-9509
pISSN - 0971-7587
DOI - 10.47203/ijch.2021.v33i03.026
Subject(s) - medicine , economic shortage , government (linguistics) , perspective (graphical) , economic growth , artificial intelligence , linguistics , philosophy , computer science , economics
The Oxford University-AstraZeneca’s vector-based vaccine called Covishield (ChAdOx1 nCoV- 19 Vaccine) is being manufactured and distributed by Serum Institute of India (SII). National roll out of this vaccine was in a phased manner starting from 16th January 2021. At present, many states are facing shortage of vaccines. Government of India kept changing its policy on dosing gap of Covishield vaccine based on researches. The latest recommendation citing “real-life evidence” from the UK is to extend the two doses of Covishield to 12-16 weeks. This reasonable approach will not only a breathing space for the government but also aids in free up doses for a larger number of people to get their first dose of the vaccine.